Early identification of patients with severe COVID-19 at increased risk of in-hospital death: a multicenter case-control study in Wuhan

Abstract

Background: Most evidence regarding the risk factors for early in-hospital mortality in patients with severe COVID-19 focused on laboratory data at the time of hospital admission without adequate adjustment for confounding variables. A multicenter, age-matched, case-control study was therefore designed to explore the dynamic changes in laboratory parameters during the first 10 days after admission and identify early risk indicators for in-hospital mortality in this patient cohort. Methods: Demographics and clinical data were extracted from the medical records of 93 pairs of patients who had been admitted to hospital with severe COVID-19. These patients had either been discharged or were deceased by March 3, 2020. Data from days 1, 4, 7, and 10 of hospital admission were compared between survivors and non-survivors. Univariate and multivariate conditional logistic regression analyses were employed to identify early risk indicators of in-hospital death in this cohort. Results: On admission, in-hospital mortality was associated with five risk indicators (ORs in descending order): aspartate aminotransferase (AST, >32 U/L) 43.20 (95% CI: 2.63, 710.04); C-reactive protein (CRP) greater than 100 mg/L 13.61 (1.78, 103.941); lymphocyte count lower than 0.6×10 9 /L 9.95 (1.30, 76.42); oxygen index (OI) less than 200 8.23 (1.04, 65.15); and D-dimer over 1 mg/L 8.16 (1.23, 54.34). Sharp increases in D-dimer at day 4, accompanied by decreasing lymphocyte counts, deteriorating OI, and persistent remarkably high CRP concentration were observed among non-survivors during the early stages of hospital admission. Conclusions: The potential risk factors of high D-dimer, CRP, AST, low lymphocyte count and OI could Zhou et al. Risk factors of in-hospital death for patients with severe COVID-19

A retrospective cohort study on COVID-19 at 2 Los Angeles hospitals: Older age, low triage oxygenation, and chronic kidney disease among the top risk factors associated with in-hospital mortality

“…Information on the patients was extracted from the electronic medical record, including age, gender, body mass index (BMI), triage oxygen saturation (which was taken on room air), diabetes, hypertension, hyperlipidemia, acute and chronic kidney disease, chronic obstructive pulmonary disease (COPD), and asthma. These patient characteristics were determined a priori as some of the common risk factors associated with COVID-19 mortality from prior literature [ 7 , 27 , 34 ] and were easily obtained from the triage evaluation. The goal of relying on triage data was to implement a triage prediction tool to easily calculate the risk of in-hospital mortality upon patient arrival to the Emergency Department.…”

The Association between Admission Procalcitonin Level and The Severity of COVID-19 Pneumonia: A Retrospective Cohort Study

“…Although the majority of symptomatic COVID-19 infections are mild, a subset of patients requires hospitalization due to severe COVID-19 pneumonia, and about 5% of patients develop a critical disease characterized by respiratory failure and/or other organs’ failure [ 2 ]. The early recognition of severe COVID-19 features is crucial to identify patients at risk of poor outcome, create an opportunity for early interventions, personalize the treatment protocols, allow a better allocation of valuable resources, e.g., ventilators and intensive care unit (ICU) beds, and improve the outcomes [ 3 ]. The host factors are the main determinants of the disease severity, although viral factors have also been implicated [ 4 , 5 ].…”

Inosine: A broad-spectrum anti-inflammatory against SARS-CoV-2 infection-induced acute lung injury via suppressing TBK1 phosphorylation

“…Cytokine storms cause life-threatening systemic inflammation characterized by immune cell hyperactivation and the release of proinflammatory cytokines including interleukin-6 (IL-6), interferons, and tumor necrosis factor-alpha (TNF-α) [ 10 ]. Our previous study and several recent articles indicated that a sharp increase in pleiotropic cytokine IL-6 content was associated with acute respiratory distress syndrome (ARDS), sepsis, and even death in patients with COVID-19 [ 11 , 12 ]. IL-6 receptor antagonists have been widely administered in human clinical trials.…”